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Ghrelin, a powerful appetite-stimulating hormone secreted by the stomach, is modified by an octanyl side
chain on its third amino acid, a serine, which is essential for its activity. A recent study (Yang et al., 2008)
reports identification of the enzyme catalyzing the addition of this octanyl, GOAT.Ghrelin was thus named (from ghre, the
Proto-Indo-European root of the word
‘‘grow’’) because it acutely stimulates
growth hormone secretion in both animals
and man (Kojima et al., 1999). However,
the physiological role of ghrelin in the reg-
ulation of growth hormone is unclear.
Mice with targeted deletion of either ghre-
lin (Sun et al., 2003) or its receptor, the
growth hormone secretagogue receptor
(GHS-R1a) (Wortley et al., 2004), display
normal growth, while repeated pharma-
cological administration of ghrelin to hu-
mans gives rise to rapid tachyphylaxis
(diminished response to repeated admin-
istration) of growth hormone release.
Ghrelin has also been found to potently
stimulate food intake in rodents (Kojima
et al., 1999) and humans (Wren et al.,
2001), and this effect is maintained on
repetitive administration (Tscho¨p et al.,
2000). Circulating levels of ghrelin are
raised in starvation, increase before initia-
tion of food intake, and decrease greatly
postprandially. Mice lacking either ghrelin
(Wortley et al., 2005) or GHS-R1a (Zigman
et al., 2005) are protected from diet-in-
duced obesity on a high-fat diet. On a nor-
mal diet, they have increased fat oxidation
but normal body weight (Sun et al., 2003;
Wortley et al., 2004).
In addition to the originally reported
form of ghrelin, a biologically active vari-
ant that lacks the Gln residue at position
14 is produced by alternate splicing (des-
Gln ghrelin). Des-Gln ghrelin is present in
much lower amounts than ghrelin but
binds with equal affinity to GHS-R1a.
Themajority of circulating ghrelin lacks the
octanyl group (des-acyl ghrelin), whose
presence is essential for binding to GHS-
R1a. There is some controversy as to the
function, if any, of des-acyl ghrelin. Differ-
ent investigators have reported that des-
acyl ghrelin can either mimic the effects
of ghrelin (for example, decreasing lipoly-sis in isolated adipocytes; Muccioli et al.
[2004]) or have the opposite effect (with
des-acyl ghrelin reducing food intake
when administered by intracerebroven-
tricular injection; Toshinai et al. [2006]). It
has been suggested that des-acyl ghrelin
binds to a receptor other than GHS-R1a.
However, the consensus opinion is that
des-acyl ghrelin at physiological concen-
trations has no measurable biological
effect.
In a recent issue of Cell, Yang et al.
(2008) identified the enzyme responsible
for the octanylation of ghrelin using an
innovative combination of bioinformatics,
based on original work by Hofmann
(2000), and cell biology. The authors rea-
soned that octanylation of ghrelin was
likely to be catalyzed by one of a family
of related enzymes, the membrane-
bound O-acyltransferases (MBOATs).
Using position-specific iterative BLAST
and previously reported sequences of
MBOATs from diverse species including
prokaryotes, plants, humans, and mice,
they identified 16 MBOATs encoded in
the mouse genome. They then isolated
clones of all of these and tested them for
their ability to catalyze octanylation of
ghrelin expressed in heterologous cell
lines. Only one of these enzymes,
MBOAT4, was found to be capable of oc-
tanylating ghrelin, and this enzyme was
renamed ghrelin O-acetyltransferase
(GOAT). In a series of comprehensive ex-
periments, the authors demonstrated
GOAT-dependent octanylation of ghrelin
in three distinct cell lines, which requires
the presence of the serine at position 3
in ghrelin. GOAT will only catalyze the ad-
dition of an octanyl group, not other acyl
groups. Finally, the authors demonstrated
that expression of GOAT is limited to the
gastrointestinal tract and testis, the pe-
ripheral tissues that express ghrelin. The
results demonstrate what appears to beCell Metaboan enzyme specific for octanylation of
ghrelin. This discovery clearly identifies
the mechanism for this unique derivatiza-
tion of a peptide hormone. Because the
nonacylated peptide does not stimulate
appetite, the question now arises of
whether GOAT activity forms a control
point in appetite regulation.
We could all eat less if we did not feel
so hungry. In countering the global
pandemic of obesity, which causes an
estimated 10,000 premature deaths per
week, an effective appetite-reduction
medication would be potentially life sav-
ing on a grand scale. The problem with
designing appetite-suppression therapies
has been achieving specificity of effect on
food intake and/or energy expenditure.
For example, many neurotransmitter mi-
metics and antagonists that interfere with
the central appetite-regulating circuits
have been developed. However, neuro-
transmitters very often have multiple roles
in different systems. Such potential anti-
obesity agents thus have numerous side
effects and so far have not proven safe
for long-term administration. With this in
mind, GOAT represents an attractive
alternative target for antiobesity therapy.
Because ghrelin is the only protein known
to be octanylated in this fashion, inhibition
of GOAT is unlikely to affect other pro-
teins, and this may obviate the side-effect
issue. In addition, small-molecule inhibi-
tors of enzymes are generally easier to
produce than small-molecule mimetics
of peptide hormones. Thus, the identifica-
tion of GOAT presents an exciting new
therapeutic target for one of the most
important but intractable of human dis-
eases. This discovery also holds the
promise of answering some of the major
questions regarding the physiological
role of ghrelin, for example, determining
whether des-acyl ghrelin has any physio-
logical functions.lism 7, March 2008 ª2008 Elsevier Inc. 193
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